JPWO2020222668A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020222668A5
JPWO2020222668A5 JP2021564120A JP2021564120A JPWO2020222668A5 JP WO2020222668 A5 JPWO2020222668 A5 JP WO2020222668A5 JP 2021564120 A JP2021564120 A JP 2021564120A JP 2021564120 A JP2021564120 A JP 2021564120A JP WO2020222668 A5 JPWO2020222668 A5 JP WO2020222668A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
seq
item
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530241A5 (https=
JP2022530241A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/PT2020/050017 external-priority patent/WO2020222668A1/en
Publication of JP2022530241A publication Critical patent/JP2022530241A/ja
Publication of JP2022530241A5 publication Critical patent/JP2022530241A5/ja
Publication of JPWO2020222668A5 publication Critical patent/JPWO2020222668A5/ja
Pending legal-status Critical Current

Links

JP2021564120A 2019-04-30 2020-04-24 Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤 Pending JP2022530241A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962840810P 2019-04-30 2019-04-30
PT115483 2019-04-30
PT11548319 2019-04-30
US62/840,810 2019-04-30
PCT/PT2020/050017 WO2020222668A1 (en) 2019-04-30 2020-04-24 Rank pathway inhibitors in combination with cdk inhibitors

Publications (3)

Publication Number Publication Date
JP2022530241A JP2022530241A (ja) 2022-06-28
JP2022530241A5 JP2022530241A5 (https=) 2023-05-08
JPWO2020222668A5 true JPWO2020222668A5 (https=) 2023-05-08

Family

ID=70775461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564120A Pending JP2022530241A (ja) 2019-04-30 2020-04-24 Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤

Country Status (9)

Country Link
US (1) US20220195059A1 (https=)
EP (1) EP3962945A1 (https=)
JP (1) JP2022530241A (https=)
KR (1) KR20220002316A (https=)
AU (1) AU2020266083A1 (https=)
BR (1) BR112021021663A2 (https=)
CA (1) CA3132656A1 (https=)
MX (1) MX2021013271A (https=)
WO (1) WO2020222668A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022272427A1 (en) * 2021-05-12 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN115718192B (zh) * 2022-11-25 2025-02-14 浙江洛兮医疗科技有限公司 一种免疫组化即用型pd-l1抗体试剂
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
PL369742A1 (en) 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
WO2004069137A2 (de) 2003-02-07 2004-08-19 Ge Bayer Silicones Gmbh & Co. Kg Verwendung von polyamino- und/oder polyammonium-polysiloxancopolymeren
WO2004097048A1 (en) 2003-04-28 2004-11-11 Canon Kabushiki Kaisha Process for assay of nucleic acid by competitive hybridization using a dna microarray
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US11596642B2 (en) * 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
US20200129473A1 (en) * 2017-07-21 2020-04-30 Eisai R&D Management Co., Ltd. Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP7212902B2 (ja) 疾患および障害の処置においてレナラーゼを制御する組成物および方法
JP2022068352A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
JP2007512243A5 (https=)
JP2009541492A5 (https=)
US20250186460A1 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
CN114080233A (zh) 给予抗cd38抗体以治疗多发性骨髓瘤的方法
CN111148764B (zh) 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合
AU2025200997A1 (en) Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells
JP2019511506A (ja) オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法
JP2024506708A (ja) 特定の乳癌の治療におけるｈｅｒ２を標的とする抗体薬物複合体の使用
JPWO2020222668A5 (https=)
JP2021523117A5 (https=)
JPWO2021183934A5 (https=)
US20250009877A1 (en) Treatment for cancer
AU2024257950A1 (en) Methods for treating multiple myeloma
JPWO2023031403A5 (https=)
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
WO2024206868A2 (en) Methods of treating tumors with anti-tigit antibodies
HK40104369A (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2024216028A1 (en) Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
CN121622859A (zh) TGF-β受体融合蛋白在制备治疗胃及胃食管结合部腺癌的药物中的用途
WO2023230605A1 (en) A method of treating solid tumor
HK40104588A (zh) 使用raf抑制剂和pd-1轴抑制剂的组合疗法
HK40123344A (zh) 一种治疗实体瘤的方法
CN118324910A (zh) Ccr8抗体的应用